Literature DB >> 17910836

[Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism].

S J Ortega Lozano1, M D Martínez Del Valle Torres, J M Jiménez-Hoyuela García, A L Gutiérrez Cardo, V Campos Arillo.   

Abstract

OBJECTIVE: To determine the diagnostic accuracy of FP-CIT SPECT in entities with and without presynaptic involvement of the nigral-striatal dopaminergic pathway in a large group of patients with movement disorders, evaluating the usefulness of quantitative analysis.
MATERIALS AND METHODS: A group of 183 consecutive patients clinically diagnosed as either having or not having degenerative Parkinsonism. These results were then contrasted with those of FP-CIT SPECT to determine the diagnostic accuracy of the procedure. The specific binding index was evaluated with ROC curves.
RESULTS: FP-CIT SPECT was highly accurate in the diagnosis of neurodegenerative Parkinsonism (sensitivity: 95 %, specificity: 90 %). Most of the false positive results arose in patients with vascular Parkinsonism and the false negative results in patients with Parkinson disease. ROC curve analysis of semiquantitative evaluation had a sensitivity of 83 % and specificity of 82 % with an optimal cut-off of 1.44. The area under the curve was not significantly different between patients </= 60 and > 60 years (0.899 vs 0.884) of age.
CONCLUSIONS: FP-CIT SPECT has a high degree of diagnostic accuracy for striatal dopaminergic involvement. No significant changes in diagnostic accuracy were seen with respect to patient age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910836

Source DB:  PubMed          Journal:  Rev Esp Med Nucl        ISSN: 0212-6982


  4 in total

1.  ECT in a patient with Parkinson's disease and schizophrenia, with dopamine transporter visualisation using 123I-ioflupane SPET.

Authors:  Paloma Fernández-Corcuera; Salvatore Aguilar; Víctor Viçens; Jaume Mora; Ana Benitez; Amparo García-Burillo; Edith Pomarol-Clotet; Peter McKenna
Journal:  J Neural Transm (Vienna)       Date:  2011-02-27       Impact factor: 3.575

2.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Authors:  S A Eshuis; P L Jager; R P Maguire; S Jonkman; R A Dierckx; K L Leenders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

3.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

4.  Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.

Authors:  John T O'Brien; Wolfgang H Oertel; Ian G McKeith; Donald G Grosset; Zuzana Walker; Klaus Tatsch; Eduardo Tolosa; Paul F Sherwin; Igor D Grachev
Journal:  BMJ Open       Date:  2014-07-03       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.